

OLIVER study

Omnipod 5 vs. Loop: Comparison of Automated Insulin DeliVERy Systems - a 12 week head to head RCT in T1D

Principal Investigators: Dr. Tom Elliott, Dr. Fatema Abdulhussein **SubInvestigator:** Dr. Dale Clayton

Study coordinator & primary contact Rachel Huang, Reem Al Shareef MD

P: 604-628-7253, rhuang@bcdiabetes.ca

Summary: OLIVER is an Open-Label, Head-to-Head Randomized Study comparing the safety and efficacy of Loop vs. Omnipod 5 AID systems in improving glycemic control and quality of life outcomes in Type 1 Diabetes.


Study location: REMOTE visits BCDiabetes 400 - 210 West Broadway, Vancouver V5Y 3W2

Background & hypothesis: The current 2025 Diabetes Canada guidelines state that Automated Insulin Delivery (AID) is the preferred treatment for T1D. AID systems consist of a continuous glucose monitor, an insulin pump, and an algorithm that adjusts a user's insulin delivery based on real-time glucose data. In Canada, the only tubeless AID options available are Omnipod 5, commercially available, or the Loop open-source smartphone application to be used off-label with the Omnipod Dash. OS-AIDs are widely used with reported safety and efficacy at levels comparable with C-AID systems. There are currently no head-to-head studies comparing commercial and open-source systems to inform clinical decision-making when patients are ready to start an automated pump.

Eligible Participants include:

- Individuals aged ≥ 2 years of age, have Type 1 Diabetes, diagnosed ≥ 3 mo ago
- Currently managing insulin with a Multiple Daily Injections, or insulin pump without automation
- GMI ≤ 13 , no diabetic emergencies in last 3 months
- Willing to use a Dexcom CGM with either 1) Omnipod Dash with Loop or 2) Omnipod 5

Treatment course and duration: This study consists of a screening period to determine baseline statistics, then participants will be randomized into either Loop or Omnipod 5 as shown in [Figure 1](#). They will have several visits with BC Diabetes for installation and training on the new AID, followed by visits as needed for adjustment (see [Figure 2](#) below). CGM data and other QoL measures will be taken at Day 28 and Day 84, after which they will continue to follow-up with their local endocrinologist for diabetes care on the system of their choice.



Odds of receiving either treatment: 50% (one half)

Link to prescreening survey: <https://bit.ly/OLIVERprescreening>

Short URL to this page = <https://bit.ly/OLIVERRCT>

Conflict of Interest statement